메뉴 건너뛰기




Volumn 13, Issue 9, 2011, Pages 597-598

HER2 in gastric cancer: A biomarker with clinical impact, but not without translational challenges

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; TRASTUZUMAB; TUMOR MARKER;

EID: 84855361780     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-011-0704-z     Document Type: Editorial
Times cited : (5)

References (6)
  • 1
    • 0022588467 scopus 로고
    • Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor
    • Yamamoto T, Ikawa S, Akaiyama T et al (1986) Similarity of protein encoded by the human cerb-B-2 gene to epidermal growth factor receptor. Nature 319:230-234 (Pubitemid 16128786)
    • (1986) Nature , vol.319 , Issue.6050 , pp. 230-234
    • Yamamoto, T.1    Ikawa, S.2    Akiyama, T.3
  • 2
    • 42449156456 scopus 로고    scopus 로고
    • Phase II trial of trastuzumab and cisplatin in patients (pts) with advanced gastric cancer (AGC) with Her2/neu overexpression/amplification
    • (ASCO Annual Meeting Proceedings) Part I., 18S, June 20, abstract 4613
    • Cortes-Funes H, Rivera F, Ales I et al (2007) Phase II trial of trastuzumab and cisplatin in patients (pts) with advanced gastric cancer (AGC) with Her2/neu overexpression/amplification. J Clin Oncol 2007 (ASCO Annual Meeting Proceedings) Part I. 26[18S, June 20 Suppl]:abstract 4613
    • (2007) J Clin Oncol 2007 , vol.26 , Issue.SUPPL.
    • Cortes-Funes, H.1    Rivera, F.2    Ales, I.3
  • 3
    • 77956262693 scopus 로고    scopus 로고
    • Trastuzumab in combination with chemotherapy versus chemotherapy alone for the treatment of HER2 positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomized controlled trial
    • Bang YJ, Van Cutsem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for the treatment of HER2 positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial. Lancet 376:687-697
    • (2010) Lancet , vol.376 , pp. 687-697
    • Bang, Y.J.1    Van Cutsem, E.2    Feyereislova, A.3
  • 4
    • 84855386274 scopus 로고    scopus 로고
    • Consensus of the Spanish Society of Medical Oncology (SEOM) and Spanish Society of Pathology (SEAP) for HER2 testing in gastric carcinoma
    • Gomez-Martin C, Concha A, Corominas JM et al (2011) Consensus of the Spanish Society of Medical Oncology (SEOM) and Spanish Society of Pathology (SEAP) for HER2 testing in gastric carcinoma. Clin Transl Oncol 13:636-651
    • (2011) Clin Transl Oncol , vol.13 , pp. 636-651
    • Gomez-Martin, C.1    Concha, A.2    Corominas, J.M.3
  • 5
    • 77956895978 scopus 로고    scopus 로고
    • HER2 diagnostics in gastric cance: Guideline validation and development of standardized immunohistochemical testing
    • Ruschoff J, Dietel M, Baretton G et al (2010) HER2 diagnostics in gastric cance: guideline validation and development of standardized immunohistochemical testing. Virchows Arch 457:299-307
    • (2010) Virchows Arch , vol.457 , pp. 299-307
    • Ruschoff, J.1    Dietel, M.2    Baretton, G.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.